MedTrace Logo

Effect of Tafoxiparin to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest

NCT03001193 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 361

Last updated 2020-04-29

No results posted yet for this study

Summary

The study will be designed as a double-blind, placebo-controlled, parallel-group, dose-finding study with one group treated with placebo and three groups treated with tafoxiparin in three different infusion concentration levels, respectively. The intravenous infusion will be initiated by a pre-defined bolus dose infusion.

Conditions

  • Labor, Obstetric

Interventions

DRUG

DF 01

DRUG

Oxytocin

DRUG

Placebo

Sponsors & Collaborators

  • Dilafor AB

    lead INDUSTRY

Principal Investigators

  • Gunvor Ekman-Ordeberg, MD, PhD · Dilafor AB

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-11-30
Completion
2019-05-31

Countries

  • Denmark
  • Finland
  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03001193 on ClinicalTrials.gov